Ignite Creation Date:
2025-12-24 @ 11:17 PM
Ignite Modification Date:
2026-01-02 @ 2:09 AM
Study NCT ID:
NCT03481556
Status:
TERMINATED
Last Update Posted:
2022-12-19
First Post:
2018-03-06
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
Sponsor:
Oncopeptides AB
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
OP-104
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None